Indications: Solid tumors

PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation).

Mechanism of action / Target

PMC-309 binds to VISTA expressing cells such as myeloid-derived suppressor cells (MDSC) that inhibits VISTA-mediated T cell inactivation and proliferation.


The discovery of preclinical efficacy and mechanism of action is in progress using human VISTA-KI model in mice. The production of samples needed for the GLP-toxicity study is underway for the IND filing.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.